In vitro comparative activity of meropenem with 15 other antimicrobial agents against 1798 Pseudomonas aeruginosa isolates in a French multicenter study

Clinical Microbiology and Infection

Volumn 5, Issue 8, 1999, Pages 499-503

  Husson, M O ^a   Richet, H ^b   Aubert, A ^c   Cattoen, C ^d   Chardon, A ^e   Jarlier, V ^f   Izard, D ^a   Lecaillon, E ^g   Melon, M ^g   Morel, A ^g   Nicolas, M H ^g  

^a UNIV LILLE   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c CHG Saint Etienne   (France)

^d CHG Valenciennes   (France)

^e CHG Aix en Provence   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT; AZTREONAM; BETA LACTAM; CARBAPENEM; CEFEPIME; CEFSULODIN; CEFTAZIDIME; CIPROFLOXACIN; CLAVULANIC ACID; FOSFOMYCIN; GENTAMICIN; IMIPENEM; MEROPENEM; NETILMICIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TAZOBACTAM; TICARCILLIN; TIMENTIN; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CLINICAL TRIAL; DRUG DEVELOPMENT; FRANCE; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; HUMAN CELL; IMMUNODIFFUSION; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SEROTYPING;

EID: 0032829323     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.1999.tb00180.x     Document Type: Article

References (23)

1. Giamarellou H, Touliatou K, Koratzanis G, et al. Nosocomial consequences of antibiotic usage. Scand J Infect Dis 1986; Suppl 49: 182-8.
2. Chen HY, Yvan M, Ibrahim-Elmaghoul IB, Livermore DM. National survey of susceptibility to antimicrobials amongst clinical isolates of Pseudomonas aeruginosa. J Antimicrob Chemother 1995; 35: 521-34.
3. Richard P, Le Floch C, Chamoux C, Pannier M, Espaze E, Richet H. Pseudomonas aeruginosa outbreak in a burn unit: role of antimicrobials in the emergence of multiple resistant strains. J Infect Dis 1994; 170: 377-83.
4. Colom K, Fernandez-Aranguiz A, Suinaga E, Cisterna R. Emergence of resistance to beta-lactam agents in Pseudomonas aeruginosa with group I beta-lactamases in Spain. Eur J Clin Microbiol Infect Dis 1995; 14: 964-71.
5. Karlowsky JA, Saunders MH, Harding GAJ, Hoban DJ, Zhanel GG. In vitro characterization of aminoglycoside adaptive resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1996; 40: 1387-93.
6. Livermore DM, Yang YJ. β-Lactamase lability and inducer power of newer β-lactam antibiotics in relation to their activity against β-lactamase inducibility mutants of Pseudomonas acruginosa. J Infect Dis 1987; 155: 775-82.
7. Radberg G, Nilson Le, Svensson S. Development of quinolone-imipenem cross resistance in Pseudomonas aeruginosa during exposure to ciprofloxacin. Antimicrob Agents Chemother 1990; 34: 2142-7.
8. Miro E, Navarro F, March F, Sanchez F, Mirebilis B. Emergence of different resistance mechanisms in Pseudomonas aeruginosa in a patient treated with imipenem. Eur J Clin Microbiol Infect Dis 1995; 14: 731-2.
9. Buscher KH, Cullmann W, Dick W, Opferkuch W. Imipenem resistance in Pseudomonas aeruginosa resulting from diminished expression of an outer membrane protein. Antimicrob Agents Chemother 1987; 31: 703-8.
10. Li XZ, Ma DM, Livermore DM, Nikaido H. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: active-efflux as a contributory factor to β-lactam resistance. Antimicrob Agents Chemother 1994; 38: 1742-52.
11. Mayhall CG. In Wenzel RP, ed. Prevention and control of nosocomial infections. Baltimore: Williams & Wilkins, 1993: 614-64.
12. Edwards JR, Turner PJ, Wannop C, Withnell ES, Grindley AJS, Nairn K. In vitro antibacterial activity of SM-7338, a carbapenem antibiotic with stability to dehydropeptidase I. Antimicrob Agents Chemother 1989; 33: 215-22.
13. Moellering RC, Eliopoulos GM, Sentochnick DE. The carbapenems: new broad spectrum β-lactam antibiotics. J Antimicrob Chemother 1989; 24(suppl A): 1-7.
14. Acar J, Chardon H, Choutet P, et al. Comité d l'antibiogramme de la Société Française de Microbiologie. Path Biol 1996; 44: I-VII.
15. Garcia-Rodriguez JA, Blazquez AM, Fresnadillo MJ, Garcia-Sanchez E, Garcia-Sanchez JE, Trujillano-Martin I. In vitro activity of meropenem against ciprofloxacin-resistant Enterobacteriaceae and Pseudomonas aeruginosa. J Chemother 1996; 8: 358-64.
16. Iaconis JP, Pitkin DH, Sheikh W, Nadler HL. Comparison of antibacterial activities of meropenem and six other antimicrobials against Pseudomonas aeruginosa isolates from North American studies and clinical trials. Clin Infect Dis 1997; 24(suppl 2): S191-6.
17. Pitt TL, Livermore DM, Pitcher D, Vatopoulos AC, Legakis NJ. Multiresistant serotype O12 Pseudomonas aeruginosa: evidence of a common strain in Europe. Epidemiol Infect 1989; 103: 565-76.
18. Bingen E, Bonacorsi S, Rohrlich P, et al. Molecular epidemiology provides evidence of genotypic heterogeneity of multidrug-resistant Pseudomonas aeruginosa serotype O12 outbreak isolates from a pediatric hospital. J Clin Microbiol 1996; 34: 3226-9.
19. Bert F, Lambert-Zechovsky N. Comparative distribution of resistance pattern and serotypes in Pseudomonas aeruginosa isolates from intensive care units and other wards.J Antimicrob Chemother 1996; 37: 809-13.
20. Legakis NJ, Koukoubanis N, Papavassiliou J, Papapetropoulou M. Serotypes of Pseudomonas aeruginosa in clinical specimens in relation to antibiotic susceptibility. J Clin Microbiol 1982; 16: 458-63.
21. Voutsinas D, Mavroudis TH, Avlamis A, Giomarellou H. In vitro activity of meropenem, a new carbapenem, against multiresistant Pseudomonas aeruginosa compared with that of other antipseudomonal antimicrobials. J Antimicrob Chemother 1989; Suppl 24: 143-7.
22. Perez FJ, Cimeno C, Navarro D, Garcia De Loinas J. Meropenem permeation through the outer membrane of Pseudomonas aeruginosa can involve pathways other than OprD porin channel. Chemotherapy 1996; 42: 210-14.
23. Masuda N, Sakagawa E, Ohya S. Outer membrane proteins responsible for multiple drug resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1995; 39: 645-9.